MinervaX provides clinical and leadership update

– Completed enrolment of 150 pregnant women in a Phase 2 study in South Africa and dosing started in an additional 50 pregnant women in Uganda, as part of same study

– Phase 1 booster study started in the United Kingdom

– Regulatory approval obtained from Danish Medicines Agency and UK MHRA for the initiation of a Phase 2 study in pregnant women, in Denmark and United Kingdom

– Vaccine Expert and Biotech Entrepreneur Gerd Zettlmeissl appointed new Chairman of the Board of Directors

– Leading vaccine industry veterans join Scientific Advisory Board

COPENHAGEN, DenmarkOct. 7, 2021 /PRNewswire/ — MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces clinical progress on its maternal GBS vaccine as well as multiple additions to its leadership teams.

Read more…